Therapeutic IGF-I Receptor Inhibition Alters Fibrocyte Immune Phenotype in Thyroid-Associated Ophthalmopathy

Investigators demonstrated that teprotumumab, an anti-insulin-like growth factor I receptor inhibitor, attenuated constitutive expression and induction by the thyroid-stimulating hormone of MHC II and these B7 members in CD34+ fibrocytes.